Strs Ohio Has $927,000 Stake in Retrophin Inc (RTRX)

Strs Ohio decreased its holdings in shares of Retrophin Inc (NASDAQ:RTRX) by 7.4% during the third quarter, according to the company in its most recent disclosure with the SEC. The fund owned 32,300 shares of the biopharmaceutical company’s stock after selling 2,600 shares during the quarter. Strs Ohio owned 0.08% of Retrophin worth $927,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also added to or reduced their stakes in the company. FNY Investment Advisers LLC bought a new position in Retrophin in the second quarter worth approximately $136,000. Sei Investments Co. bought a new position in Retrophin in the second quarter worth approximately $141,000. Xact Kapitalforvaltning AB bought a new position in Retrophin in the first quarter worth approximately $206,000. Hartford Investment Management Co. bought a new position in Retrophin in the second quarter worth approximately $216,000. Finally, Trexquant Investment LP bought a new position in Retrophin in the second quarter worth approximately $273,000.

Shares of NASDAQ RTRX opened at $25.81 on Monday. The firm has a market cap of $1.05 billion, a price-to-earnings ratio of -17.20 and a beta of 1.19. Retrophin Inc has a 12-month low of $20.09 and a 12-month high of $33.00. The company has a current ratio of 5.04, a quick ratio of 4.99 and a debt-to-equity ratio of 0.60.

Retrophin (NASDAQ:RTRX) last issued its earnings results on Thursday, November 1st. The biopharmaceutical company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.53) by ($0.39). Retrophin had a negative return on equity of 35.43% and a negative net margin of 69.38%. The company had revenue of $40.70 million for the quarter, compared to analyst estimates of $44.36 million. During the same quarter in the previous year, the company posted $0.15 earnings per share. The company’s quarterly revenue was up 1.0% compared to the same quarter last year. As a group, equities research analysts expect that Retrophin Inc will post -2.12 EPS for the current year.

In other Retrophin news, CEO Steve Aselage sold 12,000 shares of the company’s stock in a transaction dated Friday, August 31st. The shares were sold at an average price of $32.00, for a total transaction of $384,000.00. Following the transaction, the chief executive officer now directly owns 257,883 shares in the company, valued at $8,252,256. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Corporate insiders own 3.67% of the company’s stock.

RTRX has been the topic of several research analyst reports. Jefferies Financial Group initiated coverage on Retrophin in a research note on Tuesday, October 30th. They issued a “buy” rating and a $44.00 price objective on the stock. Zacks Investment Research raised Retrophin from a “sell” rating to a “hold” rating in a research note on Thursday, September 27th. BidaskClub raised Retrophin from a “hold” rating to a “buy” rating in a research note on Tuesday, August 28th. Finally, Canaccord Genuity assumed coverage on Retrophin in a research report on Friday, August 17th. They set a “buy” rating on the stock. One equities research analyst has rated the stock with a hold rating and five have assigned a buy rating to the company’s stock. The company currently has a consensus rating of “Buy” and a consensus target price of $43.50.

Retrophin Profile

Retrophin, Inc, a biopharmaceutical company, focuses on the development, acquisition, and commercialization of therapies for the treatment of rare diseases. Its marketed products include Chenodal, a synthetic oral form of chenodeoxycholic acid for the treatment of radiolucent stones in well-opacifying gallbladders; Cholbam, a cholic acid capsule to treat pediatric and adult patients with bile acid synthesis disorders due to single enzyme defects, and for adjunctive treatment of patients with peroxisomal disorders; and Thiola, a tiopronin tablet for the treatment of cystinuria.

Recommended Story: Liquidity

Want to see what other hedge funds are holding RTRX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Retrophin Inc (NASDAQ:RTRX).

Institutional Ownership by Quarter for Retrophin (NASDAQ:RTRX)

Receive News & Ratings for Retrophin Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Retrophin and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply